Clindamycin IP price index

Clindamycin IP price December 2025 and outlook (see chart below)

• India:US$67.97/KG, -0.1% down

Business Analytiq assumes no responsibility or liability for any errors or omissions in the content of this site. The information contained in this site is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness, or timeliness.

Clindamycin IP price index

This post is a summary of the Clindamycin IP price developments. The price developments of Clindamycin IP are expressed in US$ prices converted FX rates applicable at the time when the price was valid. Clindamycin IP price index developments are calculated from multiple separate sources of data to ensure statistical accuracy.

The outlook for Clindamycin IP prices is generated from different inputs including:

• Very recent price developments of immediate cost drivers of Clindamycin IP prices
• Recent price developments of underlying feedstocks which drive the price of Clindamycin IP
• Market futures for both cost drives and feedstocks of Clindamycin IP prices
• Adjustment of current supply/demand imbalances in the Clindamycin IP market
• Longer term trends in likely demand conditions

What is Clindamycin IP and what is it used for

Clindamycin (often supplied as clindamycin phosphate or clindamycin hydrochloride in pharmacopeial / IP-grade forms) is a lincosamide antibiotic used to treat bacterial infections — particularly anaerobic infections and certain Gram-positive infections (skin and soft tissue infections, respiratory infections, bone and joint infections, dental infections) and as a topical agent for acne. It is commonly used when penicillins are inappropriate or ineffective.

How is Clindamycin IP produced

Industrial production typically begins from lincomycin (a natural product) which is chemically transformed into clindamycin by selective modification (for example by a Vilsmeier-type reaction and subsequent steps) and then converted to a pharmaceutically acceptable salt (phosphate or hydrochloride) and purified to meet IP/API specifications. Several proprietary multi-step syntheses and patent-protected routes exist; recent literature also describes one-pot or improved processes to raise yield and reduce waste. Typical large-scale manufacturing uses organic solvents, intermediate transformations and crystallization / salt-formation steps to obtain high-purity API.

How large is the global market for Clindamycin IP

Market estimates depend on the specific clindamycin form (API, hydrochloride salt, or topical phosphate formulations). Representative industry reports show the clindamycin-hydrochloride market in the ~US$1.5–1.9 billion range in the mid-2020s (different reports and product scopes give slightly different figures), while clindamycin-phosphate (often used in topical acne preparations) market estimates report around US$0.24–0.79 billion in the early-to-mid 2020s. Other API-focused reports place the clindamycin-hydrochloride API market at roughly US$300–$460 million (reporting scopes and years differ). In short: depending on whether you look at finished products, topical combinations, or API only, values reported across market research firms range from a few hundred million to nearly two billion USD.

Where is Clindamycin IP produced

Clindamycin APIs and finished forms are manufactured globally. Major producing countries and regions include India and China (large volumes of API and topical intermediates), but there are also manufacturers and finished-product producers in the United States, parts of Europe (Italy, Denmark and others), and suppliers listed from Singapore and elsewhere. Several specialized API manufacturers and chemical companies appear in trade directories and pharma supplier listings. Production is therefore geographically distributed, with a concentration of API manufacturing in Asia (India/China) and formulation/finished-dosage production spread across Asia, Europe and North America.